$HAE
HAEMONETICS CORP Stock $hae

$hae Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000031314314000097 Filed on July 31, 2014

Income Statement

Concept	2014 Q2	2013 Q2
Revenue	$224.5M	$219.5M
YoY Change	2.25%	24.4%
Cost Of Revenue	$118.2M	$108.1M
YoY Change	9.32%	25.21%
Gross Profit	$106.3M	$111.4M
YoY Change	-4.61%	23.64%
Gross Profit Margin	47.34%	50.75%
Selling, General & Admin	$92.56M	$106.8M
YoY Change	-13.34%	57.95%
% of Gross Profit	87.09%	95.87%
Research & Development	$15.38M	$11.21M
YoY Change	37.23%	19.13%
% of Gross Profit	14.47%	10.06%
Depreciation & Amortization	$20.50M	$18.40M
YoY Change	11.41%	64.29%
% of Gross Profit	19.29%	16.52%
Operating Expenses	$107.9M	$118.0M
YoY Change	-8.54%	53.21%
Operating Profit	-$1.666M	-$6.608M
YoY Change	-74.79%	-150.52%
Interest Expense	-$2.500M	-$2.600M
YoY Change	-3.85%	-966.67%
% of Operating Profit
Other Income/Expense, Net	-$2.543M	-$2.641M
YoY Change	-3.71%	-886.01%
Pretax Income	-$4.209M	-$9.249M
YoY Change	-54.49%	-168.95%
Income Tax	-$560.0K	-$1.375M
% Of Pretax Income
Net Earnings	-$3.649M	-$7.874M
YoY Change	-53.66%	-180.45%
Net Earnings / Revenue	-1.63%	-3.59%
Basic Earnings Per Share	-$0.07	-$0.15
Diluted Earnings Per Share	-$0.07	-$0.15
COMMON SHARES
Basic Shares Outstanding	51.74M shares	51.23M shares
Diluted Shares Outstanding	51.74M shares	51.23M shares

Balance Sheet

Concept	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$139.9M	$166.3M
YoY Change	-15.87%	-29.53%
Cash & Equivalents	$139.9M	$166.3M
Short-Term Investments
Other Short-Term Assets	$65.10M	$72.40M
YoY Change	-10.08%	41.41%
Inventory	$207.5M	$196.7M
Prepaid Expenses
Receivables	$156.7M	$156.0M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$569.3M	$591.4M
YoY Change	-3.73%	9.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$294.1M	$255.0M
YoY Change	15.34%	53.38%
Goodwill	$337.2M	$341.5M
YoY Change	-1.25%	196.84%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.41M	$10.92M
YoY Change	-4.71%	-1.4%
Total Long-Term Assets	$907.4M	$888.3M
YoY Change	2.16%	128.97%
TOTAL ASSETS
Total Short-Term Assets	$569.3M	$591.4M
Total Long-Term Assets	$907.4M	$888.3M
Total Assets	$1.477B	$1.480B
YoY Change	-0.2%	59.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$55.21M	$47.92M
YoY Change	15.23%	41.02%
Accrued Expenses	$49.50M	$41.50M
YoY Change	19.28%	64.68%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.931M	$32.43M
YoY Change	-94.05%	1241.91%
Total Short-Term Liabilities	$165.9M	$187.8M
YoY Change	-11.68%	54.05%
LONG-TERM LIABILITIES
Long-Term Debt	$429.0M	$448.1M
YoY Change	-4.26%	16861.36%
Other Long-Term Liabilities	$38.42M	$39.38M
YoY Change	-2.44%	81.03%
Total Long-Term Liabilities	$467.4M	$487.5M
YoY Change	-4.12%	1898.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$165.9M	$187.8M
Total Long-Term Liabilities	$467.4M	$487.5M
Total Liabilities	$633.3M	$675.3M
YoY Change	-6.22%	361.58%
SHAREHOLDERS EQUITY
Retained Earnings	$409.3M	$390.3M
YoY Change	4.86%	-4.93%
Common Stock	$405.2M	$378.9M
YoY Change	6.95%	10.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$815.1M	$774.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.477B	$1.480B
YoY Change	-0.2%	59.42%

Cashflow Statement

Concept	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$3.649M	-$7.874M
YoY Change	-53.66%	-180.45%
Depreciation, Depletion And Amortization	$20.50M	$18.40M
YoY Change	11.41%	64.29%
Cash From Operating Activities	$13.74M	$13.40M
YoY Change	2.51%	2323.51%
INVESTING ACTIVITIES
Capital Expenditures	$37.09M	$13.09M
YoY Change	183.26%	55.1%
Acquisitions	$0.00	$23.12M
YoY Change	-100.0%
Other Investing Activities	$0.00	-$22.60M
YoY Change	-100.0%	3128.57%
Cash From Investing Activities	-$37.02M	-$35.65M
YoY Change	3.85%	287.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$26.47M	$0.00
YoY Change
Debt Paid & Issued, Net	$254.0K	$233.0K
YoY Change	9.01%	7.37%
Cash From Financing Activities	-$28.81M	$9.504M
YoY Change	-403.15%	-41.43%
NET CHANGE
Cash From Operating Activities	$13.74M	$13.40M
Cash From Investing Activities	-$37.02M	-$35.65M
Cash From Financing Activities	-$28.81M	$9.504M
Net Change In Cash	-$52.09M	-$12.74M
YoY Change	308.87%	-267.84%
FREE CASH FLOW
Cash From Operating Activities	$13.74M	$13.40M
Capital Expenditures	$37.09M	$13.09M
Free Cash Flow	-$23.35M	$310.0K
YoY Change	-7631.29%	-103.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	55213000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	53562000	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	156733000	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	164603000	USD
CY2014Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2076000	USD
CY2014Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3113000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1410000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	565000	USD
CY2014Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	404686000	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	402611000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3500000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3000000	USD
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1865000	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1676000	USD
CY2014Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	347000	USD
CY2013Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	427000	USD
CY2014Q2	us-gaap	Assets Assets	1476731000	USD
CY2014Q1	us-gaap	Assets Assets	1514178000	USD
CY2013Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	327000	USD
CY2014Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	261000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	569305000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	622976000	USD
CY2014Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	97416000	USD
CY2014Q2	us-gaap	Average Remaining Maturity Of Foreign Currency Derivatives1 AverageRemainingMaturityOfForeignCurrencyDerivatives1	P1Y
CY2013Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	121000	USD
CY2014Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	224000	USD
CY2014Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	7870000	USD
CY2014Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	33100000	USD
CY2014Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	31700000	USD
CY2014Q1	us-gaap	Capitalized Software Development Costs For Software Sold To Customers CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers	15600000	USD
CY2014Q2	us-gaap	Capitalized Software Development Costs For Software Sold To Customers CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers	17000000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139943000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	192469000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	179120000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166328000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-12792000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-52526000	USD
CY2014Q2	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	1400000	USD
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52041189	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51430080	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51430080	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52041189	shares
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	514000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	520000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4495000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8134000	USD
CY2014Q2	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP	2530000	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	118210000	USD
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	108131000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	14144000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	14173000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	1184000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	1119000	USD
CY2013Q2	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	840000	USD
CY2014Q2	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	285000	USD
CY2014Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	28366000	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	29664000	USD
CY2013Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18357000	USD
CY2014Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	20511000	USD
CY2014Q1	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	3824000	USD
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	1754000	USD
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	673000	USD
CY2014Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1255000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2014Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-432000	USD
CY2013Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-51000	USD
CY2013Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.149
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	49495000	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	54913000	USD
CY2014Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1100000	USD
CY2013Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1000000	USD
CY2013Q2	us-gaap	Employee Stock Ownership Plan Esop Cash Contributions To Esop EmployeeStockOwnershipPlanESOPCashContributionsToESOP	2666000	USD
CY2013Q2	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	960000	USD
CY2014Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.133
CY2014Q2	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	101694000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	110030000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	264560000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	271159000	USD
CY2014Q2	us-gaap	Fiscal Period Duration FiscalPeriodDuration	P364D
CY2014	us-gaap	Fiscal Period Duration FiscalPeriodDuration	P364D
CY2014Q2	us-gaap	Foreign Currency Cash Flow Hedge Derivative At Fair Value Net ForeignCurrencyCashFlowHedgeDerivativeAtFairValueNet	154000000	USD
CY2014Q1	us-gaap	Foreign Currency Cash Flow Hedge Derivative At Fair Value Net ForeignCurrencyCashFlowHedgeDerivativeAtFairValueNet	157900000	USD
CY2014Q2	us-gaap	Foreign Currency Contract Asset Fair Value Disclosure ForeignCurrencyContractAssetFairValueDisclosure	1401000	USD
CY2014Q2	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	673000	USD
CY2014Q1	us-gaap	Foreign Currency Derivative Instruments Not Designated As Hedging Instruments At Fair Value Net ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet	72900000	USD
CY2014Q2	us-gaap	Foreign Currency Derivative Instruments Not Designated As Hedging Instruments At Fair Value Net ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet	66000000	USD
CY2014Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-414000	USD
CY2013Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-154000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	337237000	USD
CY2014Q1	us-gaap	Goodwill Goodwill	336768000	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	111412000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	106278000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9249000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4209000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-560000	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1375000	USD
CY2013Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	906000	USD
CY2014Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2097000	USD
CY2014Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5695000	USD
CY2013Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7377000	USD
CY2014Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7918000	USD
CY2013Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14100000	USD
CY2014Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9569000	USD
CY2013Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12845000	USD
CY2014Q2	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	589000	USD
CY2013Q2	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-6110000	USD
CY2014Q2	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	313000	USD
CY2013Q2	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	4727000	USD
CY2013Q2	us-gaap	Interest Paid Net InterestPaidNet	2401000	USD
CY2014Q2	us-gaap	Interest Paid Net InterestPaidNet	2011000	USD
CY2014Q2	us-gaap	Interest Rate Derivative Assets At Fair Value InterestRateDerivativeAssetsAtFairValue	353000	USD
CY2014Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	117770000	USD
CY2014Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	126385000	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	197661000	USD
CY2014Q2	us-gaap	Inventory Net InventoryNet	207487000	USD
CY2014Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	72508000	USD
CY2014Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	74464000	USD
CY2014Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7383000	USD
CY2014Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6638000	USD
CY2014Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	95662000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1514178000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1476731000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	165868000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	216928000	USD
CY2014Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	8543000	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	45630000	USD
CY2014Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1931000	USD
CY2014Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	429010000	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	392057000	USD
CY2014Q2	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	4600000	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-28811000	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9504000	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35647000	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37021000	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13738000	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13402000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-7874000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-3649000	USD
CY2014Q2	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	5	segment
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	107944000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	118020000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6608000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1666000	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10410000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10654000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-51000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-845000	USD
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	57153000	USD
CY2014Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	59710000	USD
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38415000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37641000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2543000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2641000	USD
CY2014Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	26466000	USD
CY2013Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2013Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	3459000	USD
CY2014Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	12626000	USD
CY2013Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	23124000	USD
CY2014Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2014Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37085000	USD
CY2013Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13092000	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50969000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	54099000	USD
CY2013Q2	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	262000	USD
CY2014Q2	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	1687000	USD
CY2013Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	569000	USD
CY2014Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	64000	USD
CY2014Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2223000	USD
CY2013Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5849000	USD
CY2013Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	686000	USD
CY2014Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	590000	USD
CY2013Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	673000	USD
CY2014Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	511000	USD
CY2013Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	372000	USD
CY2014Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	154000	USD
CY2013Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	385000	USD
CY2014Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	75000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	294100000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	271437000	USD
CY2014Q2	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	794000	USD
CY2014Q2	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	254000	USD
CY2013Q2	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	233000	USD
CY2014Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	8531000	USD
CY2013Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11209000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15382000	USD
CY2013Q2	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	1300000	USD
CY2014Q2	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	1400000	USD
CY2014Q2	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	74000000	USD
CY2013Q2	us-gaap	Restructuring Charges RestructuringCharges	23469000	USD
CY2014Q2	us-gaap	Restructuring Charges RestructuringCharges	15065000	USD
CY2013Q1	us-gaap	Restructuring Reserve RestructuringReserve	3262000	USD
CY2013Q2	us-gaap	Restructuring Reserve RestructuringReserve	22945000	USD
CY2014Q2	us-gaap	Restructuring Reserve RestructuringReserve	25719000	USD
CY2014Q1	us-gaap	Restructuring Reserve RestructuringReserve	23636000	USD
CY2013Q2	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	-327000	USD
CY2014Q2	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	-356000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	224488000	USD
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	219543000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2622
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	433347000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	409307000	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	106811000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	92562000	USD
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	3013000	USD
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	3489000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2262
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51741000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0141
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0164
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.49
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.78
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M24D
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2014Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	96853	shares
CY2013Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	81465	shares
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	815072000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	837888000	USD
CY2014Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-104000	USD
CY2013Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-2776000	USD
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2013Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51231000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51231000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51741000	shares
CY2014Q2	hae	Employee Stock Purchase Plan Espp Weighted Average Purchase Price Of Shares Purchased EmployeeStockPurchasePlanESPPWeightedAveragePurchasePriceOfSharesPurchased	25.85
CY2013Q2	hae	Employee Stock Purchase Plan Espp Weighted Average Purchase Price Of Shares Purchased EmployeeStockPurchasePlanESPPWeightedAveragePurchasePriceOfSharesPurchased	32.73
CY2014Q2	hae	Numberof Global Product Families NumberofGlobalProductFamilies	4	product
CY2014Q2	hae	Percentage Of Net Sales Generated Outside Of Us PercentageOfNetSalesGeneratedOutsideOfUs	0.462
CY2014Q2	hae	Restructuringand Related Cost Expected Cost Payablein Cash RestructuringandRelatedCostExpectedCostPayableinCash	58000000	USD
CY2013Q2	hae	Restructuringand Transformation Costs RestructuringandTransformationCosts	33492000	USD
CY2014Q2	hae	Restructuringand Transformation Costs RestructuringandTransformationCosts	22993000	USD
CY2014	hae	Term Of Each Quarter TermOfEachQuarter	P91D
CY2014Q2	hae	Term Of Each Quarter TermOfEachQuarter	P91D
CY2013Q2	hae	Transfers From Inventory To Fixed Assets TransfersFromInventoryToFixedAssets	3357000	USD
CY2014Q2	hae	Transfers From Inventory To Fixed Assets TransfersFromInventoryToFixedAssets	2443000	USD
CY2013Q2	hae	Transformation Costs TransformationCosts	10023000	USD
CY2014Q2	hae	Transformation Costs TransformationCosts	7928000	USD
CY2014Q2	dei	Amendment Flag AmendmentFlag	false
CY2014Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-28
CY2014Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2014Q2	dei	Document Period End Date DocumentPeriodEndDate	2014-06-28
CY2014Q2	dei	Document Type DocumentType	10-Q
CY2014Q2	dei	Entity Central Index Key EntityCentralIndexKey	0000313143
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51430080	shares
CY2014Q2	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q2	dei	Entity Registrant Name EntityRegistrantName	HAEMONETICS CORP

Files In Submission

Name	View Source	Status
0000313143-14-000097-index-headers.html	Edgar Link	pending
0000313143-14-000097-index.html	Edgar Link	pending
0000313143-14-000097.txt	Edgar Link	pending
0000313143-14-000097-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hae-20140628.xml	Edgar Link	completed
hae-20140628.xsd	Edgar Link	pending
hae-20140628_cal.xml	Edgar Link	unprocessable
hae-20140628_def.xml	Edgar Link	unprocessable
hae-20140628_lab.xml	Edgar Link	unprocessable
hae-20140628_pre.xml	Edgar Link	unprocessable
haeq1june2015doc.htm	Edgar Link	pending
haeq1june2015exhibit10anil.htm	Edgar Link	pending
haeq1june2015exhibit10bnil.htm	Edgar Link	pending
haeq1june2015exhibit10ctn.htm	Edgar Link	pending
haeq1june2015exhibit10dpen.htm	Edgar Link	pending
haeq1june2015exhibit311.htm	Edgar Link	pending
haeq1june2015exhibit312.htm	Edgar Link	pending
haeq1june2015exhibit321.htm	Edgar Link	pending
haeq1june2015exhibit322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HAE
HAEMONETICS CORP Stock $hae

2014 Q2 Form 10-Q Financial Statement

#000031314314000097 Filed on July 31, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HAE HAEMONETICS CORP Stock $hae

2014 Q2 Form 10-Q Financial Statement

#000031314314000097 Filed on July 31, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HAE
HAEMONETICS CORP Stock $hae